Please assess the completion status of the following clinical trial:

Trial Title: F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult, non-pregnant patients with biopsy-proven or clinically obvious primary, recurrent or metastatic breast cancer~* Breast cancer from ER+ primary that is seen on other imaging tests; tumor ER expression must have been confirmed by immunohistocytochemistry of primary tumor or recurrent disease~* At least one site of disease 1.5 cm or greater is needed to meet the spatial resolution limits of PET imaging~* Patients must have been off tamoxifen or other estrogen receptor blocking agents for at least 6 weeks and off chemotherapy for 3 weeks for the initial baseline FES~* Patients must be selected for an endocrine targeted therapy regimen for treatment of their breast cancer by the referring oncologist; selected treatments may be part of experimental treatment protocols for which the patient would be separately consented~* Patients must be willing to undergo serial imaging procedures~* Patients must agree to allow access to clinical records regarding response to treatment and long term follow up~Exclusion Criteria:~* An inability to lie still for the tests~* Individuals weighing more than 300 lb; (this is the weight limit of the scanner table)~* Pregnant or lactating; women of childbearing potential with either a positive or no pregnancy test at baseline are excluded~* Any other life-threatening illness (e.g. serious, uncontrolled concurrent infection or clinically significant cardiac disease - congestive heart failure, symptomatic coronary artery disease, cardiac arrhythmia not well controlled with medication)~* Use of tamoxifen, Faslodex, diethylstilbestrol (DES) or any other ER blocking agent \< 6 weeks or chemotherapy \< 3 weeks prior to imaging scan~* Unwillingness or inability to give informed consent~* Uncontrolled diabetes mellitus (fasting glucose \> 200 mg/dL)~* Adult patients who require monitored anesthesia for PET scanning

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (F-18 FES PET/CT) (Type: EXPERIMENTAL): Patients undergo F-18 FES PET/CT scan at baseline. Patients also undergo F-18 FES PET/CT and FDG PET/CT between 1-12 weeks after starting therapy, and then 1-12 weeks after the second FES PET/CT scan. Repeat FDG PET may be omitted in patients on selective estrogen receptor degrader.

Based on this trial design, predict the completion outcome and termination type (if applicable).